Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G).
I. McCaffery
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. Tudor
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Deng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. Badola
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. L. Kindler
Consultant or Advisory Role - Abbott Laboratories; Amgen; Bristol-Myers Squibb; Clovis Oncology; Merck; Otsuka; Roche
C. S. Fuchs
Consultant or Advisory Role - Alnylam; Amgen; AstraZeneca; Bristol-Myers Squibb; ImClone Systems; Merck; POZEN; Roche
E. Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
L. Chen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
J. L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen